Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Aerie Pharmaceuticals Inc (AERI) USD0.001

Sell:$19.05 Buy:$24.82 Change: $0.45 (2.21%)
NASDAQ:0.10%
Market closed |  Prices as at close on 14 October 2019 | Switch to live prices |
Sell:$19.05
Buy:$24.82
Change: $0.45 (2.21%)
Market closed |  Prices as at close on 14 October 2019 | Switch to live prices |
Sell:$19.05
Buy:$24.82
Change: $0.45 (2.21%)
Market closed |  Prices as at close on 14 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Contact details

Address:
4301 Emperor Blvd Ste 400
DURHAM
27703-7615
United States
Telephone:
+1 (919) 2375300
Website:
www.aeriepharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AERI
ISIN:
US00771V1089
Market cap:
$925.68 million
Shares in issue:
45.94 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Vicente Anido
    Chairman of the Board, Chief Executive Officer
  • Thomas Mitro
    President, Chief Operating Officer
  • Casey Kopczynski
    Co-Founder, Chief Scientific Officer
  • Richard Rubino
    Chief Financial Officer, Treasurer, Secretary
  • Eric Carlson
    Vice President - Research & Development
  • John LaRocca
    General Counsel and Assistant Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.